Bioasis is dedicated to delivering hope to patients suffering with neurological diseases and disorders. Our breakthrough science focuses on transporting medicines across the blood-brain barrier, providing a path to hundreds of previously untreatable diseases of the central nervous system.
1 in 6 People Worldwide
Neurological disease affects 1.25 billion people worldwide, and the incidence of these disorders is only increasing. Bioasis is determined to deliver effective treatments to patients suffering with these diseases.
Our Science
A Barrier to Better Health
The blood-brain barrier plays an essential role in protecting the brain from blood-borne disease. However, it also blocks otherwise effective medicine from reaching the brain. Most drugs created to treat central nervous system diseases and disorders fail because they aren't optimally designed to be delivered in sufficient quantities to the brain.
Blood-Brain Barrier
Transporting Treatment
The Bioasis xB3 platform provides researchers with a path for the delivery of treatments across the blood-brain barrier and into the brain. Our technology offers a solution to a problem that for decades has blocked development of effective treatment of neurological disorders.
Our Platform
Latest News
Bioasis Establishes U.S. Presence with Office in ConnecticutOct 10, 2017
The Company also launches new website bioasis.us
biOasis Appoints Christopher P. Lowe, M.B.A. as Chief Financial Officer and Board AdvisorOct 2, 2017
Lowe brings extensive experience serving as an executive and board member for early, research-stage biotechnology companies
biOasis Announces Voting Results for 2017 Annual MeetingSep 21, 2017
The Company welcomes new board members Dr. Nancy Stagliano, Dr. Deborah Rathjen and Dr. Maha Radhakrishnan